ARID1A

Across TCGA pan-cancer cohorts, ARID1A RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of ARID1A’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where ARID1A RNA is repressed in tumor relative to normal tissue. In most cancer types ARID1A is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

THCA, HNSC, and LIHC are the cancer types where ARID1A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARID1A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	All	−0.451	<.001	9	view →
HNSC	All	All	+0.645	<.001	8	view →
LIHC	All	All	+0.637	<.001	7	view →
STAD	All	II,III,IV	+0.781	.001	6	view →
BLCA	Female	III,IV	+0.597	.003	6	view →
BRCA	All	III,IV	+0.497	<.001	6	view →
KIRC	All	II,III,IV	−0.318	.004	5	view →
KICH	All	All	−0.869	<.001	4	view →
LUSC	All	All	+0.407	.002	4	view →
LUAD	All	All	+0.309	.009	4	view →
CHOL	All	All	+1.402	<.001	3	view →
PRAD	All	All	+0.408	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

ARID1A–THCA

Open the THCA breakdown →